TORONTO--(Marketwire - January 22, 2009) - OpenCell BioMed Inc. (OTCBB: OCBM) -- OpenCell BioMed Inc. announces completion of its phase-2 fatigue testing on its proprietary TI FOAM™ dental implant design in conjunction with the Canadian National Research Council (CNRC). The CNRC phase-2 report concluded:
1. All implants were easily implanted. 2. No titanium particle debris was observed after implant retrieval, suggesting that the titanium foam has sufficient abrasion resistance, at least for the conditions used in this study. 3. The initial stability of all implants was good. However, the torque required to unscrew the implants was slightly larger for the implants without foam. This finding was associated with the enlargement of the holes caused by the abrasion of the bone by the foam. A modification of the design was proposed to address this issue and increase the contact area between the implant and the crestal bone. 4. Important amount of bone interlocked in the foam was observed after implantation. It is believed that this will provide good implant stability after bone remodeling. 5. The fatigue limits of the implants with and without foam were similar. This is a positive finding considering the results reported in the literature on the effect of porous coating on the fatigue of Ti6Al4V implants.
The full report will be posted on our website www.opencellbiomed.com.
OpenCell BioMed Inc. is a medical device designer and manufacturer specializing in innovative designs merging proprietary biomedical materials with human cell biology. The company is developing a unique line of dental implants and related products for sale worldwide. OpenCell BioMed is differentiated by its proprietary paradigm shift surface coating/material TI FOAM™. Used as the bone to implant interface enabling dental implant systems, it has greater short and long term stability with minimally invasive techniques compared to traditional dental implant systems.
“The completion of phase-2 brings us another step closer to the completion of our research and development project with the CNRC and subsequent commercialization of the TI FOAM™ dental implant line.” (Dr. Mislav Pavelic, CEO-OpenCell BioMed Inc.)
About OpenCell BioMed Inc.
OpenCell BioMed is a medical device designer and manufacturer specializing in innovative designs merging proprietary biomedical materials with human cell biology. The company is developing a unique line of dental implants and related products for sale worldwide.
About Dental Implants
Dental implants are designed as permanent replacements for missing teeth. A dental implant is a metal post that is surgically placed into the bone under the gums. The purpose of the placement into the bone is to encourage the integration of the dental implants. The bone actually grows around the dental implant, making the tooth secure. A replacement tooth is attached to the titanium post by means of a final abutment. Did you know that dental implants are frequently the best treatment option for replacing missing teeth? Rather than resting on the gum line like removable dentures, or using adjacent teeth as anchors like fixed bridges, dental implants are long-term replacements.
Cautionary Statement Regarding Forward-Looking Information: Except for statements of historical fact relating to the Corporation, certain information contained herein constitutes forward-looking statements. Forward-looking statements are frequently characterized by words such as “potential,” “estimate,” “plan,” “expect,” “project,” “intend,” “believe,” “anticipate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change. The reader is cautioned not to place undue reliance on forward-looking statements.
For further information, contact:
Karen Willoughby
Corporate Relations Group
Phone: 1-888-323-0929
Website: www.opencellbiomed.com
E-mail: Email Contact